Life Science News

Catalytic Data Science Joins Integrated DNA Technologies Align Program

Partners in science unite to deliver cutting-edge next generation sequencing solutions (NGS) to researchers

Global genomics solutions provider Integrated DNA Technologies (IDT) welcomes Catalytic Data Science to its Align Program, bolstering IDT's roster of preferred sequencing providers working collectively to advance genomics research. As an Align Program partner, Catalytic Data Science will help drive awareness of IDT's rhAmpSeq™ CRISPR Analysis System to support the scientific community in quantifying the full array of on- and off-target genome editing events in their research. The system, which combines IDT's leading Alt-R™ CRISPR genome editing reagents with innovative data analysis technology, was recognized with a 2021 Life Science Industry Award in the "Most Innovative New Product — Genomics" category by Bioinformatics Inc.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005068/en/

Integrated DNA Technologies and Catalytic Data Science unite to deliver cutting-edge next generation sequencing solutions (NGS) to researchers. As an IDT Align program partner, Catalytic Data Science will help drive awareness of IDT's rhAmpSeq™ CRISPR Analysis System to support the scientific community in quantifying the full array of on- and off-target genome editing events in their research. The system, which combines IDT's leading Alt-R™ CRISPR genome editing reagents with innovative data analysis technology, was recognized with a 2021 Life Science Industry Award in the

Integrated DNA Technologies and Catalytic Data Science unite to deliver cutting-edge next generation sequencing solutions (NGS) to researchers. As an IDT Align program partner, Catalytic Data Science will help drive awareness of IDT's rhAmpSeq™ CRISPR Analysis System to support the scientific community in quantifying the full array of on- and off-target genome editing events in their research. The system, which combines IDT's leading Alt-R™ CRISPR genome editing reagents with innovative data analysis technology, was recognized with a 2021 Life Science Industry Award in the "Most Innovative New Product — Genomics" category by Bioinformatics Inc. (Graphic: Business Wire)

"As innovation and demand for more scientific breakthroughs continue to drive the genomics revolution, researchers are facing the tipping point for data analysis," said Rajan Kapadia, IDT's VP of Global Sales and Marketing. "Catalytic Data Science's integrated knowledge management and informatics platform, coupled with IDT's proprietary rhAmpSeq technology, can support researchers' workflow needs and transform the way data is turned into knowledge. Adding Catalytic Data Science to IDT's Align Program provides yet another solution to help the scientific community improve research outcomes and advance their important work."

Catalytic Data Science is a groundbreaking discovery informatics platform designed to integrate large volumes of scientific resources, data, and analytic tools in a single, secure, and scalable environment. The platform, which earned a "20 Most Promising Data Analytics Solutions Provider — 2018" recognition from CIO Review, streamlines the research workflow by uniting all digital resources a life sciences company needs into one integrated, interoperable, and secure platform to fuel life sciences innovation and drug discovery.

Kuan-Fu Ding, PhD, Chief Scientific Officer at Catalytic Data Science, added, "Collaborating with like-minded life science companies is becoming increasingly important for accelerating CRISPR and NGS-based research projects. We couldn't be prouder to provide our R&D workflow solutions as a complement to IDT's rhAmpSeq technology to help expedite R&D milestones and enable more research and discovery."

Launched in 2021, the IDT Align Program broadens access to services and solutions that help move genomics research projects forward. The program unites some of the most comprehensive genomic sequencing servicers in the world who are aligned in a shared mission of collaboration and have resolved to break down research barriers. Align Program members help to ensure accessibility of NGS tools and resources for researchers who need a sequencing provider tailored for their specific research. For a list of members and program benefits, visit https://www.idtdna.com/pages/products/next-generation-sequencing/idt-align .

About IDT

Integrated DNA Technologies, Inc. (IDT) , a company of Danaher Corporation (NYSE:DHR), develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore. For more information, please visit www.idtdna.com and follow on Twitter , LinkedIn , Facebook , YouTube , and Instagram .

About Catalytic Data Science

Catalytic Data Science built a groundbreaking discovery informatics platform designed to increase the predictability of life sciences research by scaling the computational workflows used by R&D teams to discover and develop new products. Comprised of a team of life scientists, data scientists, and software engineers, Catalytic Data Science delivers the digital tools, team networking, and knowledge management solutions required to reach scientific milestones faster. Increasing the speed of research cycles while decreasing cost enables life sciences companies to monetize their research faster to drive business forward. For more information, visit the company's LinkedIn , Facebook , and Twitter , or https://insight.catalyticds.com .

Disclaimer: RUO - For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.

Kristina Sarenas
Manager of PR
800-328-2661 (USA & Canada)
+1 319-626-8400 (outside USA)
idtpr@idtdna.com

News Provided by Business Wire via QuoteMedia

DHR

INN Video: Ian Graham of Discovery Harbour Resources

Discovery Harbour Resources Corp. (TSXV:DHR) President and CEO, Ian Graham, spoke with Resource Investing News on its flagship project, Wabassi, located in northern Ontario. “We’ve put our arms around an entire Greenstone Belt hosted VMS Mineral District. This is, as far as I’m aware, Canada’s most recent discovery of a new mineral district,” states Mr. Graham. In 2013, investors can expect the mobilization of drilling on the project, with news expected to come out in July. “Based on that news, we will be financing the Company a little further in the fall,” Mr. Graham says.

Keep reading...Show less

FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy

  • The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy
  • Spinal cord stimulation is proven to be more effective than conventional medical management in the treatment of chronic pain 1,2

Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its Proclaim™ XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication. People who receive therapy from the Proclaim XR SCS system will also be able to use Abbott's NeuroSphere™ Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely.

Roughly 34.2 million Americans, or 10.5% of the U.S. population, have diabetes. 3 Diabetic neuropathy, one of the complications of diabetes, is a type of damage seen predominately in nerves running to the feet. 4 During their lifetime, approximately 50% of adults with diabetes will develop peripheral neuropathy, which may include symptoms such as pain and numbness in the legs, feet and hands. 5

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic recommends rejection of below-market mini-tender offer by TRC Capital Investment Corporation

Medtronic plc (NYSE:MDT) recently became aware that TRC Capital Investment Corporation (TRC) has made an unsolicited mini-tender offer to purchase up to 1,500,000 Medtronic ordinary shares, representing approximately 0.1% of the company's outstanding ordinary shares. TRC's offer price of $77.25 per share in cash is approximately 4.5% lower than the $80.91 closing price of Medtronic ordinary shares on January 20, 2023 the last closing price prior to commencement of the offer.

Medtronic does not recommend or endorse TRC's unsolicited below-market mini-tender offer. Further, because the offer is at a price significantly below the current market price of Medtronic ordinary shares, Medtronic recommends that shareholders not tender their shares. Medtronic is not affiliated or associated with TRC, its mini-tender offer, or the mini-tender offer documentation.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook

  • Fourth-quarter sales of $10.1 billion ; full-year 2022 sales of $43.7 billion
  • Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent
  • Full-year 2022 GAAP diluted EPS of $3.91 ; adjusted diluted EPS of $5.34
  • Continues to strengthen portfolio with steady cadence of new product approvals

Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022 .

  • Fourth-quarter sales of $10.1 billion , which were negatively impacted by an expected year-over-year decline in COVID-19 testing-related sales, decreased 12.0 percent on a reported basis and 6.1 percent on an organic basis, which excludes the impact of foreign exchange.
  • Excluding COVID-19 testing-related sales 1 , fourth-quarter sales decreased 1.4 percent on a reported basis and increased 5.4 percent on an organic basis.
  • Excluding COVID-19 testing-related sales 2 and U.S. infant formula sales that were impacted by manufacturing disruptions 3 , full-year 2022 sales increased 1.9 percent on a reported basis and 7.4 percent on an organic basis.
  • GAAP diluted EPS was $0.59 in the fourth quarter. Excluding specified items, adjusted diluted EPS was $1.03 .
  • Abbott issues full-year 2023 guidance for diluted EPS from continuing operations on a GAAP basis of $3.05 to $3.25 and full-year adjusted EPS from continuing operations of $4.30 to $4.50 .
  • Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of high-single digits 4 and COVID-19 testing-related sales of around $2.0 billion .
  • In October, Abbott's market-leading FreeStyle Libre ® continuous glucose monitoring system was named the "Best Medical Technology" of the last 50 years by the Galien Foundation.
  • In December, Abbott announced U.S. Food and Drug Administration (FDA) approval of its Eterna™ spinal cord stimulation system — the smallest implantable, rechargeable system currently available for the treatment of chronic pain. 5
  • In January, Abbott announced U.S. FDA approval of its minimally invasive Navitor™ transcatheter aortic valve implantation (TAVI) system for people with severe aortic stenosis who are at high risk for surgery.

"We significantly exceeded the EPS guidance we provided at the beginning of last year despite challenging global business conditions," said Robert B. Ford , chairman and chief executive officer, Abbott. "Our R&D pipeline continues to be highly productive with several recent and upcoming new product launches that position us well going forward."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Singular Health Group Limited

Completion of Global3D Acquisition

Medical technology company Singular Health Group Ltd (ASX: SHG) (“Singular Health”, or “the Company”) is pleased to advise that it has completed the acquisition of the assets of Global3D Pty Ltd (“Global3D”) as previously announced on 6 December 2022. The acquisition is the culmination of over two years of working together with Global3D to investigate and develop enhanced software, technology and 3D printing processes for a range of medical devices, including customised ankle foot orthotics and individualised prosthetics.

Keep reading...Show less

Johnson & Johnson Reports Q4 and Full-Year 2022 Results

  • 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%*
  • 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%*
  • 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%*
  • 2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 increasing by 3.6%*
  • Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of $10.50, reflecting growth of 3.5%*

Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. "Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges," said Joaquin Duato, Chairman of the Board and Chief Executive Officer. "I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value."

OVERALL FINANCIAL RESULTS

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Johnson & Johnson Reports Q4 and Full-Year 2022 Results

  • 2022 Fourth-Quarter reported sales decline of 4.4% to $23.7 Billion primarily driven by unfavorable foreign exchange and reduced COVID-19 Vaccine sales vs. prior year. Operational growth excluding COVID-19 Vaccine of 4.6%*
  • 2022 Fourth-Quarter earnings per share (EPS) of $1.33 decreasing 24.9% and adjusted EPS of $2.35 increasing by 10.3%*
  • 2022 Full-Year reported sales growth of 1.3% to $94.9 Billion primarily driven by strong commercial execution partially offset by unfavorable foreign exchange. Operational growth of 6.1%*
  • 2022 Full-Year earnings per share (EPS) of $6.73 decreasing 13.8% and adjusted EPS of $10.15 increasing by 3.6%*
  • Company guides 2023 adjusted operational sales growth excluding COVID-19 Vaccine of 4.0%* and adjusted operational EPS of $10.50, reflecting growth of 3.5%*

Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. "Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges," said Joaquin Duato, Chairman of the Board and Chief Executive Officer. "I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value."

OVERALL FINANCIAL RESULTS